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Abstract
Background: We determined the expression of forkhead box Q1 (FoxQ1), E-cadherin (E-cad), Mucin 1 (MUC1), vimentin
(VIM) and S100 calcium binding protein A4 (S100A4), all epithelial-mesenchymal transition (EMT) indicator proteins in non-
small cell lung cancer (NSCLC) tissue samples. We also investigated the relationship between these five proteins expression
and other clinicopathologic factors in NSCLC. Finally, we assessed the potential value of these markers as prognostic
indicators of survival in NSCLC’s patients.
Methods: Quantitative real-time PCR and immunohistochemistry were used to characterize the expression of the FoxQ1
mRNA and protein in NSCLC. Expression of transcripts and translated products for the other four EMT indicator proteins was
assessed by immunohistochemistry in the same clinical NSCLC samples.
Results: FoxQ1 mRNA and protein were up-regulated in NSCLC compared with normal tissues (P=0.015 and P,0.001,
respectively). Expression of FoxQ1 in adenocarcinoma was higher than in squamous cell carcinoma (P=0.005), and high
expression of FoxQ1 correlated with loss of E-cad expression (P=0.012), and anomalous positivity of VIM (P=0.024) and
S100A4 (P=0.004). Additional survival analysis showed that high expression of FoxQ1 (P=0.047) and E-cad (P=0.021) were
independent prognostic factors.
Conclusion: FoxQ1 maybe plays a specific role in the EMT of NSCLC, and could be used as a prognostic factor for NSCLC.
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Introduction
Lung cancer is the most frequently occurring cancer type, and
the leading cause of cancer death globally, with greater mortality
than breast, prostate, and colorectal cancer combined [1,2]. Over
the past three decades in China, lung cancer mortality has
increased by 465%, with these malignancies becoming the second
leading cause of death after liver cancer [3]. Despite great advance
in the treatment of cancers in recent years, the prognosis for
patients with lung cancer remains poor, with 5-year survival rates
less than 15% [4,5]. Most patients with lung cancer are at an
advanced period of the disease at the time of diagnosis, and
approximately 85% of these cancers are non-small cell lung cancer
(NSCLC) [1,6].
Many recent studies have noted that the epithelial-mesenchymal
transition (EMT) is a critical event in tumour invasion and
metastasis in epithelial-derived cancers [7–10], including NSCLC
[11–14]. The awareness of the EMT phenomena dates back as
early as 1908. During the 1990s, EMT gained more recognition as
a possibly important mechanism in chronic diseases, such as organ
fibrosis and cancer [15]. EMT is characterized by down-regulation
of epithelial differentiation markers E-cadherin (E-cad) [16–20]
and Mucin 1 (MUC1) [21], and the up-regulation of mesenchymal
markers such as vimentin (VIM) [17–20,22,23], fibronectin
[17,20,24] and S100 calcium-binding protein A4 (S100A4) [25–
28]. Previous studies have described a key role for forkhead box
Q1 (FoxQ1) in regulating EMT and aggressiveness in human
cancer [29–32].
FOXQ1, formerly known as HNF-3/forkhead homolog 1
(HFH1), belongs to a member of the forkhead transcription factor
family [32–34], which are expressed in different tissues and play
important roles in development, metabolism, cancer and aging
[30,34]. As one of the first forkhead genes studied, FOXQ1 has
been implicated to repress smooth muscle-specific genes, such as
Sm22a and telokin in A10 cells [35]. FOXQ1 has been shown to
be a downstream mediator of Hoxa1 in embryonic stem cells [36].
Human FOXQ1, located on chromosome 6p23-25, has been
isolated and characterized [33] and plays an essential part in the
aetiology of human cancer [31,32].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39937Recent studies have described that FOXQ1 has been found to
be overexpressed in colorectal cancer [29,31] and breast cancer
[31,32], in which patients have poor clinical outcomes [31,32].
Although the overexpression of FOXQ1 in cancer cell lines
confirmed that the gene might play a role in the development of
lung cancer [29,33], the correlation between FOXQ1 expression
and EMT factors to determine its clinical significance in NSCLC
has not been previously reported.
We analysed expression of the FoxQ1 gene using quantitative
reverse transcription polymerase chain reactions (RT-PCRs) in
small, freshly frozen NSCLC tissue samples. Expression of the
FoxQ1 protein and four common EMT indicator proteins (E-cad,
MUC1, VIM and S100A4) was assessed by immunohistochemistry
using the same tissue microarray (TMA) sections. Additionally, we
investigated the relationship between the expressions of the five
genes encoding these proteins and other clinicopathological factors
in NSCLC. Finally, we assessed the potential value of these
markers as prognostic indicators of survival in patients with
NSCLC.
Methods
Patients and TMA of NSCLC samples
After a full pathological review according to the 7th Edition of
TNM in Lung Cancer [37], a panel of formalin-fixed paraffin-
embedded NSCLC tissues with corresponding tumour-adjacent
tissues undergoing surgical therapy were obtained from the
Affiliated Hospital of Nantong University between January 2005
and December 2006. Clinical data (including gender, age,
histological type, grade, stage, tumour size, differentiation, lymph
node metastasis status) were obtained from each patient’s medical
records.
Among the archival material, 103 tissue blocks from NSCLC
patients with 5 years’ follow-up survival records were available
and used for constructing the TMA. A representative area of each
tumour was selected and 2.0 mm tissue cores were used to
construct a TMA by Shanghai Outdo Biotech (China). The
quality of TMA sections was confirmed using haematoxylin-eosin
staining (H&E). The average age of the group was 62.5 years
(range: 35–81 years). Survival was calculated from the date of
surgery until the date of death or last follow-up. Furthermore, a
panel of 20 freshly frozen NSCLC tissues and matching
peritumour tissues from the same hospital mentioned above were
used in this study. Before surgical therapy, none of the patients had
received neoadjuvant chemotherapy, radiation therapy or immu-
Figure 2. Representative IHC images showing expression of FoxQ1 and EMT-related biomarkers in TMA sections of NSCLC. (A) 1 and
2: lung squamous cell carcinoma tissue pattern with H&E staining; 3 and 4: high expression of FoxQ1; 5 and 6: loss of E-cad expression; 7 and 8: strong
VIM-positive staining. (B) 1 and 2: lung adenocarcinoma tissue pattern with H&E staining; 3 and 4: positive staining for FoxQ1; 5 and 6: negative
staining for MUC1; 7 and 8: up-regulated expression of S100A4. (C) 1 and 2: lung adenocarcinoma tissue with H&E staining; 3 and 4: negative IHC for
FoxQ1; 5 and 6: strong immunological reaction of E-cad; 7 and 8: negative for S100A4. (D) 1 and 2: lung squamous cell carcinoma tissue with H&E
staining; 3 and 4: low expression of FoxQ1; 5 and 6: high expression of MUC1; 7 and 8: weak expression of VIM. Original magnification was640 for 1,
3, 5 and 7; and 6400 for 2, 4, 6 and 8.
doi:10.1371/journal.pone.0039937.g002
Figure 1. Expression of FoxQ1 mRNA in NSCLC tissues and
corresponding non-cancerous tissues. One-step q RT-PCR was
performed to confirm the expression of FoxQ1 mRNA in human tissues.
Results were normalized to GAPDH mRNA level. The FoxQ1 mRNA level
in NSCLC tissues were higher than that in peritumoural tissues with
statistical significance using a paired-samples T test. ** P,0.05. Bars
indicate standard error (S.E.).
doi:10.1371/journal.pone.0039937.g001
FoxQ1 Expression in Non-Small Cell Lung Cancer
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from the local Human Research Ethics Committee.
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted and purified from 40 freshly frozen
NSCLC tissue samples, including 20 NSCLC tissues and 20
corresponding non-cancerous tissues. Total RNA extraction,
quality control and one-step qRT-PCR were performed as
previously reported [38]. FOXQ1-specific oligonucleotide primers
(forward, 59-ACG CTG GCG GAG ATC AAC GAG-39; reverse,
59-AGG TTG TGG CGC ACG GAG TT-39) were designed to
yield a 92-bp PCR product. The data were normalized using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a refer-
ence gene (forward primer, 59-TCG GAG TCA ACG GAT TTG
GTC GT-39; reverse primer, 59-TGC CAT GGG TGG AAT
CAT ATT GGA-39).
Immunohistochemistry (IHC)
IHC was performed as described previously [39]. Deparaffi-
nized sections (4-mm thick) from array blocks were separately
stained on an Autostainer Universal Staining System (LabVision,
USA) using the following primary antibodies: mouse anti-FOXQ1
(1:300 dilution; Abcam, UK), mouse anti-E-cad (1:120; Invitrogen,
USA), monoclonal mouse anti-MUC1 (1:200; Novocastra, UK),
Table 1. Correlation of high FoxQ1 expression with clinicopathologic characteristics of NSCLC.
Clinicopathologic characteristics n FoxQ1 x
2 P
high expression (n) %
Gender 0.077 0.782
Male 71 56 78.87
Female 32 26 81.25
Age (years) 2.507 0.113
#60 40 35 87.50
.60 63 47 74.60
Tumor diameter (cm) 0.344 0.558
#3 35 29 82.86
.3 68 53 77.94
Histological type 10.709 0.005*
Squamous cell carcinoma 46 30 65.22
Adenocarcinoma 55 50 90.91
Others 2 2 100.00
Differentiation 2.431 0.297
Well 7 6 85.71
Moderate 66 55 83.33
Poorly 30 21 70.00
Lymph node metastasis 1.201 0.548
No regional lymph node metastasis 53 41 77.36
Metastasis in ipsilateral peribronchial 26 20 76.92
Metastasis in mediastinal 24 21 87.50
Stage Grouping with TNM 1.712 0.425
Stage I 50 38 76.00
Stage II 27 21 77.78
Stage III and IV 26 23 88.46
*P,0.05.
doi:10.1371/journal.pone.0039937.t001
Table 2. Relationship between the expression of FoxQ1 and
EMT indicator proteins.
Regular EMT marker





E-cad + 12 23
E-cad 2 95 9
MUC1 1.396 0.237
MUC1 + 19 65
MUC1 2 21 7
VIM 5.073 0.024*
VIM 2 20 59
VIM + 12 3
S100A4 8.374 0.004*
S100A4 2 12 20
S100A4 + 96 2
*P,0.05.
doi:10.1371/journal.pone.0039937.t002
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polyclonal rabbit anti-S100A4 (1:100; Newmarker, USA). Sec-
ondary antibodies used were: Envision goat anti-mouse HRP
(DAKO, USA), Envision goat anti-rabbit HRP (DAKO, USA).
The evaluation of immunostaining of these sections was made
blind to two trained pathologists who were unaware of the clinical
background of the samples.
The percentages of FoxQ1-positive cells were scored and placed
into four categories according to staining: 0 for 0%; 1 for 1–33%; 2
for 34–66%; and 3 for 67–100%. The FoxQ1 staining intensities
were also scored as: 0, 1, 2, or 3. The sum of the percentages and
intensity scores was used as the final FoxQ1 staining score, which
we have outlined previously [39] and has been defined as follows:
0–2, low expression; and 3–6, high expression. However, for the
positivity of the selected EMT makers (E-cad, MUC1, VIM and
S100A4), no detectable or ,10% positive staining of tumour cells
was deemed as negative, whereas $10% positive staining of
tumour cells was considered positive [40]. All samples were
evaluated at 4 6and 106magnification.
Statistical methods
The FoxQ1 mRNA level in freshly frozen NSCLC tissues and
corresponding non-cancerous tissues was normalized to GAPDH
and analysed using the Wilcoxon signed rank test for Nonpara-
metric Tests. Associations between clinicopathologic variables and
FoxQ1 protein expression were examined by x
2 tests. The chi-
squared were used to confirm the correlation between expression
of FoxQ1 and EMT indicator proteins. Survival curves were
calculated using the method of Kaplan-Meier and compared using
the log-rank test. Factors shown to be of prognostic significance in
the univariate models were evaluated using a multivariate Cox
regression model. A P-value less than 0.05 was considered to be
statistically significant. Data were analysed using STATA 9.0
software (Stata Corporation).
Results
FoxQ1 mRNA expression in NSCLC and peritumoural
tissues
Total RNA was extracted from the freshly frozen NSCLC
tissues and subjected to one-step qRT-PCR to investigate FoxQ1
mRNA expression. We also investigated samples from adjacent
matched tumour tissues. When normalized to GAPDH, the mean
expression levels of FoxQ1 mRNA in NSCLC and corresponding
non-cancerous tissue were 0.1560.02 and 0.0460.02 (P=0.015),
respectively. FoxQ1 expression was 3.75-fold higher on average in
the cancer samples than in non-malignant tissues (Fig. 1).
Table 3. Univariate and multivariate analysis of prognostic factors in NSCLC for 5 year survival.
Univariate analysis Multivariate analysis
P.|z| HR P.|z| [95% Conf. Interval]
FoxQ1 expression
High vs Low 0.023* 2.091 0.047* 1.009 4.332
Gender
Male vs Female 0.318
Age (years)
#60 and .60 0.054
Diameter (cm)
#3v s.3 0.367
E-cad 2.036 0.021* 1.111 3.730
E-cad+ vs E-cad- 0.002*
MUC1
MUC1+ vs MUC1- 0.121
VIM
VIM+ vs VIM- 0.666
S100A4
S100A4+ vs S100A4- 0.232
Histological type
Sq vs Ad 0.980
Differentiation
Well vs Moderate and Poorly 0.068
Lymph node metastasis
No vs Mip vs Mim 0.174
Stage Grouping with TNM
Stage I vs Stage II vs Stage III\IV 0.050
*P,0.05.
Sq, squamous cell carcinoma; Ad, adenocarcinoma; No, no regional lymph node metastasis; Mip, metastasis in ipsilateral peribronchial; Mim, metastasis in mediastinal;
HR, Haz. Ratio.
doi:10.1371/journal.pone.0039937.t003
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NSCLC tissues
Typical immunohistochemical staining patterns observed for
the five genes encoding the FoxQ1 and the other four indicator
EMT proteins in NSCLC are shown in Figure 2. Positive staining
for FoxQ1 was mainly localized to tumour cells and pneumocytes
in the cytoplasm and plasmalemma at different levels. While
positive nuclear staining could be seen, FoxQ1 immunolabelling
was not observed in the stroma of these tissues. High FoxQ1
expression was detected in 82/103 (50.49%) of NSCLC tissues and
was in 38 (20.39%) of the adjacent matched tumour tissues. The
data showed statistical significance using x
2 test analysis
(x
2=38.6450, P,0.001) and was consistent with FoxQ1 mRNA
levels in NSCLCs.
Positive expression of E-cad and MUC1 was localised to the cell
membrane, and a combination of the plasmalemma and
cytoplasm in NSCLC tumour cells, respectively. Positive immu-
nohistochemical staining for VIM and S100A4 in cancer cells was
observed in the cytoplasm, and a combination of the nucleus and
cytoplasm. An exception to this was the positive stromal
fibroblasts.
Relationship between expression of FoxQ1 proteins and
clinicopathological parameters in NSCLC
The associations between FoxQ1 expression and clinicopatho-
logical features of NSCLC are shown in Table 1. FoxQ1 protein
expression in adenocarcinoma was higher than in squamous cell
carcinoma with statistical significance (x
2=10.7089, P=0.005) by
x
2 test analysis. In contrast, no significant associations were seen
with patient age, gender, tumour diameter, histological grade of
the tumour, lymph node metastasis status, and stage grouping with
TNM.
Correlation between expression of FoxQ1 and the EMT
indicator proteins
The relationships between expression of FoxQ1 and the four
EMT indicator proteins were calculated and have been outlined in
Table 2. It was noted that epithelial protein loss frequencies in the
103 NSCLC tissues were 66.02% for E-cad and 18.45% for
MUC1. Abnormal mesenchymal protein expression frequencies in
the same samples were 23.30% for VIM and 68.93% for S100A4.
The result also showed that high expression of FoxQ1 correlated
with a loss of E-cad expression (x
2=6.308, P=0.012), and
anomalous positivity of VIM (x
2=1.396, P=0.024) and S100A4
(x
2=8.374, P=0.004) in clinical NSCLC samples.
Survival analysis
Several known predictive factors of poor outcome in NSCLC
were assessed to validate the cohort of patients represented by this
TMA (Table 3). High expression of FoxQ1 protein (P=0.023) and
low expression of E-cad protein (P=0.002) showed a statistically
significant association with five year survival by Cox regression
univariate analysis. In addition to these two genetic markers, other
NSCLC clinical prognostic factors, such as differentiation of
tumour and TNM stage were included in a multivariate Cox
regression model. Our data demonstrated that high FoxQ1
expression (P=0.047) and a loss of E-cad expression (P=0.021)
were confirmed to be independent prognosticators for low survival
of NSCLC.
Survival was plotted using the Kaplan–Meier method. The
results identified that the patients with a high FoxQ1 expression or
loss of E-cad expression had a significantly shorter survival time,
compared to those with low or preserved expression, respectively
(Fig. 3).
Discussion
In this study, using a TMA, we emphasized the prognostic value
of FoxQ1 expression in NSCLC. High expression of FoxQ1 was
detectable in TMAs of tumour samples and was significantly
correlated with decreased overall survival. Furthermore, the results
demonstrated that FoxQ1 expression was significantly associated
with EMT in a subgroup of patients. Through multivariate
analysis, high expression of FoxQ1 and reduced E-cad expression
were shown to be independent prognostic biomarkers for poor
overall survival. As far as we know, this is the first report of the
clinicopathological significance of FoxQ1 expression related to
EMT in clinical NSCLC tissue samples.
Recently, accumulating evidence suggests that human FoxQ1
plays a key role in regulating the EMT of breast cancer [31,32],
and aggressiveness in colon cancer [29,32]. There is considerable
proof that presence of the EMT phenomenon indicates short
survival in lung cancer [11–14]. To identify the relation between
FoxQ1 and EMT in lung carcinoma, four frequent indicator
biomarkers were investigated in lung cancer TMA using IHC.
Interestingly, our results showed that high levels of expression for
the FoxQ1 protein correlated with decreased E-cad protein
expression, and increases in VIM and S100A4 protein expression.
Some authors have shown that E-cad is linked with metastasis of
lung cancer [12]. VIM is not believed to be associated with
survival in lung cancer [14], although S100A4 has been correlated
Figure 3. Kaplan-Meier survival curves after surgical therapy in
NSCLC. (A) Curves calculated for FoxQ1 expression. High expression in
the FoxQ1 group (red line) indicated significantly less survival than low
and no expression in the FoxQ1 group (blue line). (B) Curves calculated
for E-cad expression. Lifespans of patients with positive E-cad staining
are much shorter (red line) than in patients with negative E-cad staining
(blue line).
doi:10.1371/journal.pone.0039937.g003
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research studies. We also determined the prognostic effect of EMT
marker expression by univariate and multivariate analysis. Our
results revealed that the only marker associated with outcome was
E-cad.
Recent studies have confirmed that FoxQ1 to be a valuable
prognostic indicator for poor survival in breast cancer [31,32].
However, high expression of the FoxQ1 gene was also observed in
lung cancer, gastric cancer, and colon cancer cell lines [29]. Thus,
our present results corroborate previous findings regarding FoxQ1
expression in NSCLC, especially in lung adenocarcinoma.
Although the exact mechanisms of FoxQ1’s tumorigenic effects
in NSCLC have not been described fully in our present
investigation, the molecular basis for the association between
FoxQ1 and EMT are well understood in tumor. The results
obtained from our data are in accordance with those presented in
the emerging literature, which had declared that the repression of
FoxQ1 led to an increase in E-cad expression in human carcinoma
[31,32]. Collectively, the findings in our present study corrobo-
rated that FoxQ1 could be potentially used as an EMT marker in
NSCLC.
In conclusion, we have shown that FoxQ1 was highly expressed
in NSCLC and could be used as a direct prognosticator of a
negative outcome. Also, our results supported the fact that FoxQ1
has a functional role with respect to EMT-related genes in
NSCLC.
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